- Ligand held an Investor and Analyst day on June 23rd
- Check out the Past Events page to access the webcast link and download slides from the presentations
- Visit the LGND Research notes page for complete info on LGND products and portfolio
- Topics discussed include:
- Promacta is a "now" story- codiscovered with GSK in mid 1990s
- Featured segment: thrombocytopenia in HepC - guest speaker and clinical trial leader Dr Nezam Afdhal
- breakout session #1 lab expt to show what captisol can do
- breakout session #2 LGND portfolio - "shots on goal" strategy...want large portfolio with multiple molecules and multiple therapeutics areas
- Want to fail fast, have go/no go decisions early. Company is very judicious in what decide to fund internally
- In 2011, 8 products paying royalty or material sales revenues (new language parsing? )
- Cydex acquisition double portfolio to >60 programs
- See below the jump for the rest of my (long-winded) notes: